Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYSA 1801

Next Previous
Drug Profile

SYSA 1801

Alternative Names: CPO-102 - Elevation Oncology; EO-3021; SYSA-1801

Latest Information Update: 03 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Developer CSPC ZhongQi Pharmaceutical Technology; Elevation Oncology
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clear cell sarcoma; Gastric cancer; Lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 20 Mar 2025 Discontinued - Phase-I for Clear-cell-sarcoma (Late-stage disease, Second-line therapy or greater) in China (IV)
  • 20 Mar 2025 Discontinued - Phase-I for Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in China (IV)
  • 20 Mar 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top